- In February 2024, The Children's Hospital Medical Centre in Cincinnati announced the initiation of a Phase 2 clinical trial aimed at evaluating Mirdametinib for treating Langerhans cell histiocytosis (LCH) and other histiocytic disorders. The study's focus is to determine whether Mirdametinib provides enhanced efficacy and fewer side effects compared to existing therapies, potentially offering a better treatment option for affected patients
- In October 2023, Novartis Pharmaceuticals launched a Phase 4 clinical study involving the combination of dabrafenib and trametinib in pediatric patients. The study will assess the long-term effects and safety of these two drugs when used together, with the goal of evaluating their sustained impact on children suffering from Langerhans cell histiocytosis (LCH) and related disorders
- In September 2023, Dana-Farber Cancer Institute began a Phase 2 clinical trial to investigate the potential of Clofarabine in treating Langerhans Cell Histiocytosis (LCH) and other histiocytic diseases. The trial seeks to understand Clofarabine's safety, effectiveness, and overall therapeutic potential in addressing these rare and complex disorders in pediatric and adult patients
- In June 2023, Shanghai Henlius Biotech announced the commencement of Phase 2 clinical trials of HLX208, a drug designed to treat Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD). The trials will evaluate the safety, effectiveness, and pharmacokinetics of HLX208 in adults diagnosed with these rare histiocytic disorders, aiming to establish its therapeutic viability
